Clinical Trials
GU Carcinoma
Hormone Refractory Prostate Cancer
Protocol No. CC-5013-PC-002:
A Phase 3 Study to Evaluate the efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancr.
- Principal Investigator: Thomas Cosgriff, M.D.
Protocol No. 212082-PCR-3001:
An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer who have Progressed After Taxane-Based Chemotherapy.
- Principal Investigator: Thomas Cosgriff, M.D.
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Second-line Therapy in Men with Castrate Resistant Prostate Cancer.
- Principal Investigator: N. Sekar, M.D.
Metastatic Renal Cell Carcinoma
An open-label, multicenter Phase II study to compare the efficacy and safety of RAD0001 as first-line followed by second-line sunitinib vs sunitinib as first-line followed by second-line RAD001 in the treatment of Patients with metastatic renal cell carcinoma.
- Principal Investigator: Thomas Cosgriff, M.D.
